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There is a relative lack of evidence about systemic treatments in patients with hepatocellular carcinoma 
(HCC) and moderate liver dysfunction (Child-Pugh B). In this multicenter study we retrospectively 
analyzed data from Child-Pugh B-HCC patients naïve to systemic therapies, treated with MC or 
best supportive care (BSC). To reduce the risk of selection bias, an inverse probability of treatment 
weighting approach was adopted. Propensity score was generated including: extrahepatic spread; 









activity warrants prospective evaluations.
Patients with hepatocellular carcinoma (HCC) and moderately compromised liver function (Child-Pugh B 
functional status) have limited therapeutic options due to the risk of iatrogenic liver failure. Furthermore, the 
risk-benefit ratio of available treatments may be unfavorable, because of the concurrent risk of non cancer-related 
deaths deriving from progressive hepatic failure1.
This is particularly evident in the HCC cases not amenable to surgery or locoregional treatments. For these 
patients, the availability of sorafenib depends on the different international guidelines and local regulatory 
agencies policies2. For instance, the Japanese Society of Hepatology guidelines consider Child Pugh B (CP-B) 
HCC as compromised patients for whom best supportive care (BSC) is recommended3. Instead guidelines by 
the Asia-Pacific Society for Hepatology, National Comprehensive Cancer Network, European Association for 
the Study of the Liver, and American Association for the Study of Liver Diseases are more permissive and sug-
gest a possible use of sorafenib4–6. Moreover, regulatory agencies of different countries limit the prescription of 
sorafenib only in CP-A patients (including Australia, Belgium, Canada, France, Italy, Netherlands, South Korea, 
Switzerland and Taiwan)1. This discrepancy is justified by the relative lack of clinical data of sorafenib in CP-B 
HCC. Only few CP-B patients were included in the registrative SHARP and Asian-Pacific Phase III trials to 
minimize the confounding effect of non cancer-related death7,8. An investigator-initiated RCT was specifically 
designed to assess the risk/benefit ratio of sorafenib in CP-B patients, but, unfortunately, it was prematurely 
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interrupted (ClinicalTrial.gov Identifier: NCT01405573)9. More information came from the GIDEON (Global 
Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) trial. This large Phase 4 study 
evaluated the safety and the efficacy of sorafenib in HCC patients under real-life practice conditions, and also in 
several clinically relevant subgroups, including patients with CP-B liver function10. Median overall survival (OS) 
was longer in CP-A patients than in CP-B (13.6 months vs. 5.2 months, respectively). The poor OS, paired with an 
higher rate of serious adverse events (AEs) compared to the more compensated patients, questioned the overall 
risk/benefits balance10. Previous reports11–13 had also reached similar conclusions.
It is also unlikely that CP-B patient may benefit from the new agents which emerged as successful systemic 
treatments for HCC, namely lenvatinib14, regorafenib15, and cabozantinib16. Patients with compromised liver fail-
ure were not included in these trials for the same reasons they were excluded from the SHARP trial. Furthermore, 
the rate and the severity of toxicities of these new anti-VEGFR agents are widely overlapping with those of 
sorafenib. It is therefore likely that most regulatory agencies will not approve these new drugs in CP-B subjects. 
At the moment, only a dedicated cohort of the CheckMate-040 nivolumab ongoing study17 has the specific aim of 
evaluating the efficacy and the safety of an anticancer agent in CP-B patients.
In recent years, the concept of metronomic chemotherapy has been introduced into oncology18. It is based 
on the chronic administration of chemotherapeutic agents at low doses without prolonged drug-free breaks to 
optimise the antiangiogenic properties of the drug and to reduce toxicities19,20.
Metronomic capecitabine (MC) has been tested as in first and in second line treatment for HCC patients by 
several studies, which demonstrated a good anticancer activity as well a very low rate of toxicities21–24. Also, MC 
may be effective and well tolerated in recurrent HCC after liver transplantation25. Nevertheless, none of these 
studies provided information about the potential effect of MC in CP-B HCC patients. The aim of this study was to 
retrospectively evaluate the safety and efficacy of MC as first-line treatment in this class of HCC patients.
Results
A total of 105 consecutive patients were included in our study: 35 were treated with MC (cases) from April 2006 
to February 2017, while 70 received BSC alone (controls) from October 2004 to October 2015.
Among the study population, a total of 58 patients (55.2%) were allocated to either MC or BSC in the 2006–
2011 timelapse. Of these patients, 16 received MC and 42 BSC (45.7% vs. 60.0% of the overall recruitment of the 
respective study group, p = 0.212).
Among the MC patients, 27 subjects (77%) were male, with a median age of 65 years (range 43–88). Instead, in 
the BSC group, 57 patients (81.4%) were males, with a median age of 69 years (range 37–91).
Characteristics of the two groups have been reported in Table 1. After application of the propensity score, the 
standardized differences between groups was generally minor, which suggested that baseline characteristics were 
equal (Table 2).
Median follow-up was 6 months (1.1–52.0). Median OS was 7.5 months [95% CI: 3.733–11.267]in patients 
receiving MC and 5.1 months [95% CI: 4.098–6.102] in patients receiving BSC (p = 0.013) (Fig. 1). The 1-year 
and 2-year survival rate were 31.4 vs. 17.1% and 14.3 vs. 5.7% in the MC and BSC groups, respectively, In patients 
treated with MC, median PFS was 4.5 months (95% CI: 2.5–6.5) (Fig. 2), with a median treatment duration of 4.8 
months (1.1–50.1).
Variables MC n (%) BSC n (%) P values
Total 35 70
Sex
  Male 27 (77%) 57 (81.4%) 0.613
  Female 8 (23%) 13 (18.6%)
Age median (range) 65 (43–88) 69 (37–91) 0.136
BCLC
  B 15 (42.8%) 30 (42.8%) 1.000
  C 20 (57.2%) 40 (57.2%)
Extra-hepatic spread 9 (25.7%) 12 (17.1%) 0.312
Macrovascular Invasion 14 (40%) 29 (41.4%) 1.000
ECOG - PS
  0 23 (65.7%) 39 (55.6%) 0.401
  1–2 12 (34.3%) 31 (44.4%)
Child-Pugh score
  B7 18 (51.4%) 43 (61.4%) 0.402
  B8-B9 17 (48.6%) 27 (38.6%)
AFP > 400 ng/mL 11 (31.4%) 20 (30.0%) 1.000
Etiology
  HBV 6 (17.1%) 8 (11.4%)
  HCV 18 (51.4%) 37 (52.8%) 0.703
  Non-viral 11 (31.4%) 25 (35.7%)
Table 1. Baseline characteristics of patients.
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The result of univariate unweighted Cox regression model showed a 42% reduction in death risk for patients 
on MC (HR 0.579; 95%CI: 0.370–0.906; p = 0.017) (Table 3). After weighting for potential confounders, death risk 
remained essentially unaltered (HR 0.525; 95%CI: 0.332–0.829; p = 0.006).
Best tumor response in patients treated with MC was partial response in 3 patients (8.6%), stable disease in 
10 patients (28.6%) and progressive disease in 22 patients (62.9%). No complete response was observed. Disease 
control (defined as partial response + stable disease) was associated with a significantly better survival compared 
to progressive disease (24.2 vs. 3.9 months, p < 0.001).
In the MC group, 12 patents (34.3%) experienced at least one AE, the most common of which were: fatigue 
(17.1%), hand-foot syndrome (8.5%), thrombocytopenia (8.5%), neutropenia (5.7%), anaemia (2.9%), bilirubin 
elevation (2.9%), nausea/vomiting (2.9%), mucositis (2.9%) (Table 4).
Although our study was not specifically designed to assess a correlation between dermatological AEs and 
tumor response, it should be noted that all of the 3 patients with treatment-emergent hand-foot syndrome 
attained disease control as their best radiological response (2 stable disease and 1 partial response). Further, all of 
these patients were alive after 1 year of treatment (with an OS of 29.0, 15.0 and 12.7 months, respectively).
Discussion
No systemic treatment is universally accepted for CP-B HCC. In this study we provided a proof of concept for 
future trials of MC.
As a first point, we demonstrated an improved OS in comparison with matched patients treated with BSC 
alone. The potential mechanisms of actions of MC have been previously illustrated26 and include: inhibition 
of tumor angiogenesis, reduction of the therapeutic resistance of the tumor, and activation of the adaptive and 
innate immune response27,28.
Second, we described a low rate of AEs in this fragile setting. In particular, G3-G4 toxicities occurred in 
slightly more than 5% of the patients and no severe AEs were reported. These favorable profile had been previ-
ously reported in compensated patients21–24, but safety data in CP-B patients were still lacking. The continuous 
subministration of low, fractioned, doses of drugs characterizing the metronomic regimens was the key element 







Sex 0.77 0.81 −0.095
Age 65.34 68.39 −0.308
Etiology (Viral vs. Non Viral) 0.72 0.74 −0.091
Child-Pugh score (B7 vs. B8–9) 0.49 0.39 0.201
BCLC 0.57 0.57 0
ECOG-PS 0.34 0.44 −0.202
Extrahepatic spread 0.26 0.17 0.236
Macrovascular Invasion 0.4 0.41 −0.02
AFP > 400 ng/mL 0.31 0.3 0.021
Table 2. Checking balance of confounders between MC and BSC group after weighting. MC = Metronomic 
capecitabine; BSC = Best supportive care; BCLC = Barcelona Clinic Liver Cancer; ECOG-PS = Eastern 
Cooperative Oncology Group-Performance Status; AFP = Alpha-fetoprotein.
Figure 1. Overall survival of patients treated with metronomic capecitabine and best supportive care.
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treatment (in Italy it costs less than 100 euro/month), representing a therapeutic approach easily affordable by 
most National Health Systems.
In comparison with previous studies of MC in compensated patients, the OS was unsurprisingly lower. In par-
ticular, in a post-sorafenib setting, Casadei-Gardini et al. described a median OS of 12 months23, while Trevisani 
et al. reported median survival of 9.5 months in a larger cohort24. Similarly, the median OS was 14.5 months in 
pivotal study by Brandi et al.21. Interestingly, the reduction in the risk of mortality witnessed in our study was 
not substantially different from that described in CP-A patients23,24. Even more interestingly, 37% of our patients 
achieved a best radiological response of disease control, which was associated with a significantly longer survival. 
As a result, 31.4 and 14.3% of patients in the MC treatment arm were alive at 12 and 24 months, underlying the 
possibility of “long survivors” even in this difficult clinical setting.
In the absence of head-to-head trials, a comparison with studies of sorafenib in the CP-B population is more 
difficult and potentially misleading. CT-B patients were not included in the registrative SHARP and Asian-Pacific 
trials, however a number of retrospective and prospective trials described the performance of sorafenib in CP-B 
patients (reviewed in1). Data of efficacy are quite heterogeneous, with median OS values ranging from 3.230 to 
about 8.0 months31,32. It should be underlined that the prevalence of AEs, although similar to that recorded in 
CP-A patients was still high. In particular, G3-G4 toxicities have been described in 30–32% of CP-B subjects10,33. 
Furthermore, severe AEs were more frequent in CP-B than in CP-A patients10.
As a result, median treatment duration never exceeded 2.5 months10,11,30,34–36. In comparison to these data, our 
study suggest that MC may result more easily tolerated, thus allowing a longer treatment duration (which, in its 
turn, might lead to a sustained response in a subset of patients).
Our study has some limitations, due in particular to its retrospective nature. However, it should be underlined 
that cases were consecutively selected, thus reducing potential biases. Moreover, lack of randomization was lim-
ited applying propensity score to the most common determinants of survival of HCC patients receiving systemic 
treatment. Finally, the results from the Cox regression models, remained substantially unaltered after weighting 
for potential confounders. The long timeframe of the study was another potential confounder. The treatment for 
underlying HVB infection saw its latest major innovation before the initial date of recruitment, with the licensing 
of entecavir and tenofovir in 2004 and 2015, respectively. Instead, new direct antiviral agents became available for 
the treatment of HCV infection in 2012 and 2013. To address this potential confounder, the era of recruitment 
was considered as a variable in the survival analysis. No correlation was found between era and OS.
In conclusion, this study provides a proof-of-concept of the efficacy and safety of MC in CP-B patients. Our 
results may be of help in the identification of a possible treatment for CP-B patients who can not be prescribed 
with sorafenib due to regulatory restrictions. Similarly, MC could represent a therapeutic alternative for CP-B 
patients intolerant to tyrosine-kinase inhibitors.
These promising results need confirmation through prospective RCTs.
Materials and Methods
Patients and Treatment. In this multicentre study, we retrospectively analyzed data of CP-B HCC patients 
naïve to systemic therapies, not suitable for surgical resection, liver transplantation, percutaneous ablation pro-
cedures or endovascular treatments. These patients were treated with either MC or BSC alone, as sorafenib pre-
scription is not allowed for CP-B patients by the regulatory agency of our Country.
Patients with any of the following exclusion criteria were considered not eligible for receiving MC: a) Eastern 
Cooperative Oncology Group performance status score (ECOG PS) > 2; b) severe ascites; c) moderate-to-severe 
encephalopathy; d) bilirubin ≥ 3 mg/dL; c) creatinine ≥ 1.5 mg/dL; d) platelets < 30000/mmc; e) neutro-
phils < 1000/mmc; f) peripheral neuropathy; g) symptomatic congestive heart failure, unstable angina pectoris, 
Figure 2. Progression free survival of patients treated with metronomic capecitabine.
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or serious cardiac arrhythmias. For the purposes of this study, we excluded from the analyses of the BSC group all 
of the patients who had any of the aforementioned exclusion criteria.
Patients received MC if its prescription was allowed by the centers policy and patients accepted this off-label 
treatment after receiving adequate information and signing an informed consent. Eligible patients received 
oral capecitabine at the metronomic dosage of 500 mg every 12 hours. The treatment was continued until the 
occurrence of unacceptable toxicity or radiological or symptomatic progression of HCC. No addition surgical, 
loco-regional or systemic treatments were performed during MC treatment. Patients undergoing further treat-
ments after MC permanent withdrawal (n = 2: one case of wedge resection for HCC at high risk of rupture and 
one case of trans-arterial embolization for intra-tumor bleeding) were censored at the time of the treatment.
AEs and laboratory abnormalities were graded using the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) version 4. Drug-related AEs were managed with supportive therapy, dose 
reduction or treatment suspension.
Patients were treated with BSC alone if: a) they were eligible for MC but refused this option or b) if MC 
prescription was not contemplated by the centres policies. In particular, the Oncology Unit began switching 
patients to MC in 2006, and the Internal Medicine Unit in 2010. Both groups underwent laboratory and clin-
ical follow-up monthly. Radiological examination was repeated every 2–3 months in MC patients, using mul-
tiphase computed tomography (CT) or magnetic resonance imaging (MRI). In BSC controls, imaging procedures 
were performed only when considered clinically necessary. Tumor response to MC was evaluated by modified 
Response Evaluation Criteria In Solid Tumor (mRECIST)37.
All patients provided written informed consent and the study was approved by the Independent Ethics 
Committee of the Bologna Authority Hospital S.Orsola-Malpighi. All methods were performed in accordance 
with the relevant guidelines and regulations.
Statistical analysis. Categorical variables were expressed as frequencies. Continuous variables were 
presented as median (range). OS was defined as the time from start date of the treatment to date of death. 
Variable
Univariate Multivariate
Median OS (95% CI) p-value Hazard Ratio OS (95% CI) p-value
Gender
  Male 9.1 (6.1–12.1) 0.100
  Female 5.1 (3.9–6.3)
Etiology
  Viral 6.1 (4.9–7.3) 0.309
  Non-Viral 5.1 (3.8–6.4)
Era of enrollment
  2006–2011 (0) 6.1 (4.1–8.1)
0.960































Table 3. Univariate and multivariate analysis of the correlation between OS and the analyzed independent 
variables. BCLC = Barcellona Clinic Liver Cancer; ECOG-PS = Eastern Cooperative Oncology Group-
Performance Status; AFP = Alpha-fetoprotein; MC = Metronomic capecitabine; BSC = Best supportive care.
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Progression-free survival (PFS) was defined as the time form start date of MC to the date of progression or 
death or last follow up, whichever occurred first. OS and PFS were reported as median values and expressed in 
months, with 95% confidence intervals (CI). Survival curves were estimated using the product-limit method of 
Kaplan-Meier. The role of stratification factors was analyzed with log-rank tests. Propensity score is the condi-
tional probability of being treated given a set of observed potential confounders. In this way, all the information 
from a group of potential confounders is summarized into a single balancing score variable. Propensity score 
assures that the distribution of measured baseline covariates is maintained unchanged in treated and untreated 
subjects. Standardized differences were used as balance measure to compare the difference in means in unit of the 
pooled standard deviation.
A weighted Cox Proportional Hazard Model was performed including treatment with capecitabine as covar-
iate where all confounding factors has been controlled by weighting. Propensity score weights were computed 
as 1/propensity score for patients treated with MC and 1/(1-propensity score) for patients treated with BSC. 
P-values < 0.05 were considered statistical significant. Considering the long timelapse of this study, an analysis of 
the era of enrolment (2006–2011 vs 2012–2017) was performed to reduce the risk of confounding factors.
Statistical analysis were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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